Promising Preclinical Data on CD38-SADA Justifies Buy Rating for Y-Mabs Therapeutics
Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Y-Mabs Therapeutics (YMAB – Research Report). The associated price ...
Nusano and GlyTherix Announce Lutetium-177 Supply Agreement
Nusano, a physics company transforming the production of radioisotopes, and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specializing in developing antibody ...